Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study

Gut Microbes(2025)10.1080/19490976.2025.2558071Source: DataRank Database

Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study is a research paper published in Gut Microbes (2025). On theSindex it has a DataRank of 0.487. It has been cited 13 times, with 10 citing works in its 1-hop citation network.

N/A

0.487DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access13 citations · 10 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02960659

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 6.78)OA: goldTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 81%Citation Network 19%

Base Score Contribution

0.396

From this paper's citation signal

Citation Network Contribution

0.0913

From 5 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 10 citers.

Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake
Scientific Reports20263 citations30 referencesContributes 0.046
Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice
Biomedicine & Pharmacotherapy20262 citations41 referencesContributes 0.027
The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management
Canadian Journal of Physiology and Pharmacology20262 citations58 referencesContributes 0.019
Protecting the endocrine axis in immuno-oncology: GLP-1 receptor agonists as host-directed modulators in colorectal cancer
Biomedicine & Pharmacotherapy20261 citations87 referencesContributes 0.008
Gut Microbiota, Insulin Resistance, and Alzheimer’s Disease: A Narrative Review of Mechanistic Links and Therapeutic Perspectives
International Journal of General Medicine20261 citations93 referencesContributes 0.007

Authors (14)

Sidharth P. Mishra ORCID,Shalini Jain ORCID,Faith Davis ORCID,Scott A. Gabel,Geoffrey A. Mueller ORCID

Live enrichment

PubMed:41020378 PMC:PMC12482426 OpenAlex:https://openalex.org/W4414590542

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: ZIA DK 075133

National Institutes of Health, United States

Grant: R56AG064075

National Institutes of Health, United States

Grant: R56AG069676

National Institutes of Health, United States

Grant: R21AG072379

National Institutes of Health, United States

Grant: RF1AG071762

Florida Department of Health

Grant: 22A17

Bench to Bedside Award, National Institutes of Health

Grant: #381469

Intramural NIH HHS

Grant: ZIC ES103363

Intramural NIH HHS

Grant: ZIC ES103362

National Institutes of Health

Grant: 1RF1AG071762-01

Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer’s disease

National Institutes of Health

Grant: 1R56AG064075-01A1

Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic diet

National Institutes of Health

Grant: 1ZIADK075133-04

Therapeutic targets in African-American youth with type 2 diabetes

National Institutes of Health

Grant: 1R21AG072379-01

The role of gut microbiota in the efficacy of ketogenic diet to ameliorate Alzheimer's disease

National Institutes of Health

Grant: 1ZICES103363-01

Mass Spectrometry-based Untargeted Metabolomics

National Institutes of Health

Grant: 1R56AG069676-01

Metformin and Alzheimer's disease: Underlying Mechanisms that Ameliorate Progression

National Institutes of Health

Grant: 1ZICES103362-01

NMR Research Core Facility

National Institute of Environmental Health Sciences

FWCI

6.78

Citation Percentile

1.0%

Citation Trend

2025

2026

goldLicense: public-domain

journalhttps://doi.org/10.1080/19490976.2025.2558071

publisherhttps://doi.org/10.1080/19490976.2025.2558071

publisherhttps://www.tandfonline.com/doi/pdf/10.1080/19490976.2025.2558071

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41020378

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12482426

Fields of Study

Gut microbiota and healthDiet and metabolism studiesNutritional Studies and DietAdolescentFemaleHumansMaleBacteriaBlack or African AmericanBlood GlucoseDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeHypoglycemic AgentsLiraglutideMetformin

MeSH Terms

Gastrointestinal MicrobiomeLiraglutideWhiteAdolescentBacteriaBlack or African AmericanBlood GlucoseDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsMaleMetformin

Keywords

Gut floraMetforminType 2 diabetesBile acidDiabetes mellitusLiraglutideBacteroidesMicrobiomeDiabetesMetabolomicsShort-chain Fatty AcidGlucagon-like Peptide-1 Receptor AgonistYouth-onset Type 2 DiabetesMaleBlack or African AmericanBlood GlucoseAdolescentBacteriaDiabetes Mellitus, Type 2HumansHypoglycemic AgentsFemaleResearch PaperGastrointestinal Microbiome